Zhengye Biotechnology Receives Nasdaq Non-Compliance Notice Over Minimum Bid Price Deficiency
核心洞察
Zhengye Biotechnology Holding Limited (搜索) (Nasdaq (搜索): ZYBT) received a Nasdaq notification on May 29, 2026, regarding non-compliance with the minimum US$1.00 bid price requirement.
The deficiency was triggered after the company's Class A ordinary shares traded below US$1.00 for 30 consecutive business days from April 16 to May 28, 2026.
Nasdaq (搜索) has granted the company 180 calendar days, until November 25, 2026, to regain compliance by maintaining a closing bid price of at least US$1.00 for 10 consecutive business days.
Zhengye Biotechnology Holding Limited (搜索) (Nasdaq (搜索): ZYBT), a China-based veterinary vaccine manufacturer focused on livestock vaccines, announced on June 4, 2026, that it has received a written notification from the Nasdaq Stock Market LLC regarding non-compliance with the exchange's minimum bid price requirement. The notification, dated May 29, 2026, informs the company that it no longer meets the continued listing standard under Nasdaq Listing Rule 5550(a)(2).
The rule requires listed securities to maintain a minimum bid price of US$1.00 per share. According to Nasdaq (搜索) Listing Rule 5810(c)(3)(A), a deficiency is established when a company's shares fail to meet this threshold for a period of 30 consecutive business days. Zhengye's Class A ordinary shares fell below the US$1.00 mark during the 30 consecutive business days spanning April 16, 2026, to May 28, 2026.
Compliance Timeline and Potential Remedies
The notification letter does not immediately affect the company's listing on the Nasdaq (搜索) Capital Market. Under Nasdaq rules, Zhengye has been granted a 180-calendar-day compliance period, extending through November 25, 2026. To regain compliance, the company's Class A ordinary shares must achieve a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days within this window.
Should the company fail to meet the requirement by the November deadline, it may be eligible for an additional compliance period or could face delisting proceedings. Zhengye stated that it is actively monitoring its share price and may, if deemed appropriate, consider implementing available options to address the deficiency. These options include, but are not limited to, executing a reverse share split of its outstanding Class A ordinary shares.
Business Operations Unaffected
The company emphasized that receipt of the notification letter has no impact on its ongoing business operations. Zhengye, through its operating entity Jilin Zhengye Biological Products Co., Ltd., continues to focus on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock.
With over 20 years of operational history, the company maintains a portfolio of 50 veterinary vaccines covering swine, cattle, goats, sheep, poultry, and dogs. Its products are distributed across 29 provincial regions in China and exported to international markets including Vietnam, Pakistan, and Egypt. The company operates three veterinary vaccine production floors encompassing 13 vaccine production lines, along with a quality examination center and an animal facility for vaccine development, all in accordance with Good Manufacturing Practices for Veterinary Drugs issued by China's Ministry of Agriculture and Rural Affairs.